Physicians

No free lunch for docs: Sponsored meals linked to more prescriptions

No free lunch for docs: Sponsored meals linked to more prescriptions

By

A new analysis suggests that $20 industry-sponsored meals may sway docs' prescribing habits.

Five things for pharma marketers to know: Tuesday, June 14, 2016

Five things for pharma marketers to know: Tuesday, June 14, 2016

By

Physicians debate DTC tax write-off; Novo Nordisk's Victoza shows 13% benefit in reducing cardiovascular risks; Shire to acquire Pfizer bowel drug

Leadership Exchange: Engaging the Millennial Doctor

Leadership Exchange: Engaging the Millennial Doctor

By

In partnership with inVentiv Health, MM&M found a millennial doctor to ask about her frustrations with the existing pharma marketing model to her willingness to text patients.

Merck educates doctors about biosimilars, long before it will sell one in the U.S.

Merck educates doctors about biosimilars, long before it will sell one in the U.S.

By

Drugmakers like Merck are making a big education push as they lay the groundwork for future biosimilars.

What do physicians think about biosimilars?

What do physicians think about biosimilars?

By

A SERMO poll asked physicians: Do you feel biosimilars will prove safe and effective enough for you to prescribe them when more become available?"

Five things for pharma marketers to know: Tuesday, May 17, 2016

Five things for pharma marketers to know: Tuesday, May 17, 2016

By

Online doctors prescribe drugs without adequate warnings; House lawmakers to discuss Part B proposal; obesity drugs struggle for market share

DTC Report 2016: Gut Check

DTC Report 2016: Gut Check

By

DTC is facing a new test from physicians and politicians. Here's why critics fear a deluge, and how they're pushing back.

Another physician group raises concerns about DTC

Another physician group raises concerns about DTC

By

The American College of Physicians questioned the role direct-to-consumer advertising plays in contributing to prescription drug costs.

How My GI Health changed the conversation for patients

How My GI Health changed the conversation for patients

By

The motivating force behind My GI Health met initial resistance. After all, it came from a company executive who professed that his goal was to benefit all companies within that therapeutic area.

Ironwood's McCourt bets big on data and the patient-physician dialogue

Ironwood's McCourt bets big on data and the patient-physician dialogue

By

Tom McCourt says he's "a marketing guy who hopefully understands a little about drug development" even as he guided drugs like Prilosec to market.

The truth about a doctor's day: know-it-all patients and no time for lunch

The truth about a doctor's day: know-it-all patients and no time for lunch

By

There are big changes underway in the doctor-patient relationship, a study suggests, and it's a new reality to which biopharma must adjust.

Sermo opens up platform to healthcare marketers

Sermo opens up platform to healthcare marketers

By

The Facebook for doctors launches Pages, allowing healthcare companies to establish a presence on Sermo and engage with physicians.

Finding the Right Time to Talk to Doctors

Finding the Right Time to Talk to Doctors

Time is everything, yet no one has enough of it. But especially in healthcare marketing, time and timing win customers.

Pharma turns to mobile, population data to market to docs

Pharma turns to mobile, population data to market to docs

By

Discover why even digitally native physicians can no longer abide the flood of information e-sent their way.

Five things for pharma marketers to know: Wednesday, March 2, 2016

Five things for pharma marketers to know: Wednesday, March 2, 2016

By

The doc shortage may be due, in part, to changing marriage patterns; Olympus settles anti-kickback case; U.K. says Imbruvica is too expensive

What Pharma Marketers Can Learn from Adaptive Perfectionists

What Pharma Marketers Can Learn from Adaptive Perfectionists

Perfectionists in the world of pharma marketing can no longer rely on the status quo, given current threats to traditional commercial models and the rise of digital HCP engagement.

6 insights into today's healthcare consumer

6 insights into today's healthcare consumer

Finn Partners surveyed 1,000 adults to understand how often young Americans change doctors and how they talk to pharmacists.

Marketers Rely on Email and Social Media, Rather than Face Time

Marketers Rely on Email and Social Media, Rather than Face Time

Curating personal relationships is one of the most valuable functions medical marketers can provide. The best way is through face-to-face interaction.

Five things for pharma marketers to know: Monday, December 14, 2015

Five things for pharma marketers to know: Monday, December 14, 2015

By

Physicians complain about price of Lilly's new cancer drug; AstraZeneca considers acquisition of Acerta Pharma; Shkreli plans to raise price of another old drug

PDI stockholders to vote on commercial services sale

PDI stockholders to vote on commercial services sale

By

The contract sales organization plans to sell its commercial services business to Publicis Healthcare Communications Group.

Five things for pharma marketers to know: Wednesday, November 4, 2015

Five things for pharma marketers to know: Wednesday, November 4, 2015

By

Many patients allow doctors to access their social-media accounts; Turing will reportedly lower the price of Daraprim by 10%; WebMD reports boost in traffic

EHRs, Patient Portals, and the "Four P's"

EHRs, Patient Portals, and the "Four P's"

Patient portals are an underutilized resource for a population hungry for health information.

Novartis: Cardiologists slow to advocate on behalf of new drugs

Novartis: Cardiologists slow to advocate on behalf of new drugs

By

The drugmaker said Entresto, its new heart-failure drug, brought in "modest sales" in the third quarter of 2015.

Physicians Interactive buys medical information portal

Physicians Interactive buys medical information portal

By

The deal combines two of Merck's wholly owned subsidiaries.

Off-label cases against the FDA move forward

Off-label cases against the FDA move forward

By

Amarin begins legally promoting off-label uses of its prescription fish-oil drug, while Pacira sues the FDA over the label for its pain drug, Exparel.

Will Pharma Have an Ashley Madison Moment?

Will Pharma Have an Ashley Madison Moment?

Ashley Madison's lesson must be heeded. For all the good pharma has done for the world, it has also created its share of ethical quagmires.

Physicians Interactive acquires Quantia

Physicians Interactive acquires Quantia

By

The deal is expected to complement the company's digital health platform.

Boosting Physician Referrals in Today's Hypercompetitive Healthcare Environment

Boosting Physician Referrals in Today's Hypercompetitive Healthcare Environment

The focus on boosting physician referrals might appear contrary to the current obsession with patient-centric marketing.

DTC expected to propel Afrezza awareness, not necessarily sales

DTC expected to propel Afrezza awareness, not necessarily sales

By

Havas Health developed the inhaled insulin's advertising campaign, which is slated to kick off later this summer.

Partners+Simons CEO takes helm at parent company Myelin Health

Partners+Simons CEO takes helm at parent company Myelin Health

By

With new leadership in place, the Myelin Health agency network is seeking to acquire other agencies.

OPINION

Email Newsletters